Quantitative Evaluation of Drug-Drug Interaction Potentials by in vivo Information-Guided Prediction Approach

被引:0
作者
Chen, Feng [1 ]
Hu, Zhe-Yi [2 ]
Jia, Wei-Wei [3 ]
Lu, Jing-Tao [4 ]
Zhao, Yuan-Sheng [5 ]
机构
[1] Hainan Med Univ, Sch Pharm, Hainan Prov Key Lab R&D Trop Herbs, Haikou, Hainan, Peoples R China
[2] Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Clin Pharm, Memphis, TN 38163 USA
[3] Tianjin Univ Tradit Chinese Med, Grad Sch, Tianjin, Peoples R China
[4] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA
[5] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA
关键词
Drug-drug interaction; in vivo information-guided; prediction method; CYTOCHROME-P450; 2C9; GENERAL FRAMEWORK; CYP3A4; INDUCTION; VITRO DATA; EXPOSURE; POLYMORPHISMS; INHIBITION; MODELS; IMPACT; SILICO;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Drug-drug interaction (DDI) is one important topic in drug discovery, drug development and clinical practice. Recently, a novel approach, in vivo information-guided prediction (IVIP), was introduced for predicting the magnitude of pharmacokinetic DDIs which are caused by changes in cytochrome P450 (CYP) activity. This approach utilizes two parameters, i.e. CR (the apparent contribution of the target metabolizing enzyme to the clearance of the substrate drug) and IX (the apparent effect of a perpetrator on the target CYP) to describe the magnitude of DDI between a perpetrator and a victim drug. The essential concept of this method assumes that at a given dose level, the IX for a given perpetrator remains constant whatever the victim drug is. Usually, this IVIP method is only based on information from clinical studies and does not need in vitro information. In this review, basic concept, application and extension, as well as pros and cons of the IVIP method were presented. How to apply this approach was also discussed. Thus far, this method displayed good performance in predicting DDIs associated with CYPs, and can be used to forecast the magnitude of a large number of possible DDIs, of which only a small portion have been investigated in clinical studies. The key concept of this static approach could even be implemented in dynamic modeling to assess risks of DDIs involving drug transporters.
引用
收藏
页码:761 / 766
页数:6
相关论文
共 30 条
  • [21] Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction
    Shou, Magang
    Hayashi, Mike
    Pan, Yvonne
    Xu, Yang
    Morrissey, Kari
    Xu, Lilly
    Skiles, Gary L.
    [J]. DRUG METABOLISM AND DISPOSITION, 2008, 36 (11) : 2355 - 2370
  • [22] A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology
    Soars, MG
    Gelboin, HV
    Krausz, KW
    Riley, RJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (02) : 175 - 181
  • [23] Impact of Genetic Polymorphism on Drug-Drug Interactions Mediated by Cytochromes: A General Approach
    Tod, Michel
    Nkoud-Mongo, Christina
    Gueyffier, Francois
    [J]. AAPS JOURNAL, 2013, 15 (04): : 1242 - 1252
  • [24] Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions
    Tod, Michel
    Goutelle, Sylvain
    Clavel-Grabit, Fannie
    Nicolas, Gregoire
    Charpiat, Bruno
    [J]. CLINICAL PHARMACOKINETICS, 2011, 50 (08) : 519 - 530
  • [25] Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans
    Watanabe, Takao
    Kusuhara, Hiroyuki
    Maeda, Kazuya
    Shitara, Yoshihisa
    Sugiyama, Yuichi
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 328 (02) : 652 - 662
  • [26] Yeo KR, 2013, EXPERT REV CLIN PHAR, V6, P143, DOI [10.1586/ecp.13.4, 10.1586/ECP.13.4]
  • [27] Transporter-Mediated Drug-Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies
    Yoshida, K.
    Maeda, K.
    Sugiyama, Y.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (06) : 1053 - 1064
  • [28] Application of CYP3A4 in vitro data to predict clinical drug-drug interactions;: predictions of compounds as objects of interaction
    Youdim, Kuresh A.
    Zayed, Aref
    Dickins, Maurice
    Phipps, Alex
    Griffiths, Michelle
    Darekar, Amanda
    Hyland, Ruth
    Fahmi, Odette
    Hurst, Susan
    Plowchalk, David R.
    Cook, Jack
    Guo, Feng
    Obach, R. Scott
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) : 680 - 692
  • [29] Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
    Zhao, P.
    Zhang, L.
    Grillo, J. A.
    Liu, Q.
    Bullock, J. M.
    Moon, Y. J.
    Song, P.
    Brar, S. S.
    Madabushi, R.
    Wu, T. C.
    Booth, B. P.
    Rahman, N. A.
    Reynolds, K. S.
    Berglund, E. Gil
    Lesko, L. J.
    Huang, S-M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (02) : 259 - 267
  • [30] Zhao YS, 2014, BRIT J PHARMACOL, V171, P1043, DOI 10.1111/bph.12533